Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
Authors
Keywords
-
Journal
BMJ Open
Volume 5, Issue 5, Pages e008248-e008248
Publisher
BMJ
Online
2015-05-20
DOI
10.1136/bmjopen-2015-008248
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
- (2012) F. Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy
- (2012) M. Dong et al. CLINICAL CANCER RESEARCH
- Targeting mTOR Pathways in Human Malignancies
- (2012) Angelica Fasolo et al. CURRENT PHARMACEUTICAL DESIGN
- Trends of Incidence and Survival of Gastrointestinal Neuroendocrine Tumors in the United States: A Seer Analysis
- (2012) Vassiliki L. Tsikitis et al. Journal of Cancer
- Optimizing the Surgical Effort in Patients With Advanced Neuroendocrine Neoplasm Hepatic Metastases
- (2011) Akshat Saxena et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
- (2011) Ben Lawrence et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
- (2011) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors
- (2011) Simon Schimmack et al. LANGENBECKS ARCHIVES OF SURGERY
- Translational medicine: Cancer lessons from mice to humans
- (2011) David Tuveson et al. NATURE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)
- (2011) Kjell Öberg Current Opinion in Endocrinology Diabetes and Obesity
- Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies
- (2010) Robert T. Jensen et al. CANCER
- NANETS Treatment Guidelines
- (2010) Matthew H. Kulke et al. PANCREAS
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Neuroendocrine Tumors of the Pancreas
- (2009) F. Ehehalt et al. ONCOLOGIST
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
- (2008) T. R. Halfdanarson et al. ANNALS OF ONCOLOGY
- Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis
- (2008) E.-M. Duerr et al. ENDOCRINE-RELATED CANCER
- Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
- (2008) David C. Metz et al. GASTROENTEROLOGY
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors
- (2008) Irvin M. Modlin et al. JNCI-Journal of the National Cancer Institute
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started